SV2 PET Imaging With [11C]APP311

Synaptic Density in Psychiatric Disorders Using SV2A Receptor PET Imaging With [11C]APP311

The aim of this study is to evaluate a new SV2A tracer, [11C]APP311, in healthy aging and neuropsychiatric disorders including psychotic disorders and cannabis use disorders.

The overall goal of this protocol is to study synaptic density in two psychiatric disorders (namely schizophrenia and other psychotic disorders, and cannabis use disorder) with this exciting new PET tracer. Secondary outcomes will include electroencephalography (EEG). A battery of EEG paradigms assessing sensory, perceptual, and cognitive functions will also be administered. The primary dependent measures will be traditional event related potentials (ERPs; e.g. latency and amplitude) as well as time X frequency analysis (inter-trial coherence and spectral power).

Inclusion Criteria:

• Willing and able to give voluntary written informed consent
• Male and Female subjects, age 18 to 65 years, inclusive

Exclusion Criteria:

• MRI metal exclusions and claustrophobia.
• Education completed is less than 12 years